Ventas, Inc.
VTR
$93.06
+0.41%
Ventas, Inc. is a real estate investment trust (REIT) that owns and operates a diversified healthcare portfolio of nearly 1,400 properties across senior housing, medical office buildings, hospitals, life science facilities, and skilled nursing/post-acute care, with a presence in the U.S., Canada, and the U.K. As one of the largest healthcare REITs by market capitalization, Ventas distinguishes itself through its scale and diversification across healthcare real estate segments, which provides resilience but also exposes it to operational risks in senior housing. The current investor narrative centers on the company's recovery and growth, driven by improving senior housing fundamentals, strategic investments in life sciences, and a strong balance sheet, as evidenced by a 34.6% one-year price appreciation and a 20.3% year-to-date gain, while investors debate the sustainability of this momentum amid elevated interest rates and evolving healthcare demand.…
VTR
Ventas, Inc.
$93.06
Related headlines
Investment Opinion: Should I buy VTR Today?
We rate Ventas a Buy, supported by strong revenue growth (22% YoY), improving margins, and a consensus analyst target of $100.45, implying ~8% upside. The PEG ratio of 0.80 suggests the stock is undervalued relative to its growth prospects, and the diversified portfolio reduces single-segment risk.
Sign up to view all
VTR 12-Month Price Forecast
The AI model assesses VTR as a bullish opportunity given its strong revenue acceleration, improving margins, and attractive PEG ratio. The consensus analyst target of $100.45 provides a reasonable upside, and the low beta reduces portfolio risk. However, the high forward PE and debt levels warrant caution. The stance would be upgraded if revenue growth exceeds 25% and margins continue to expand, or downgraded if growth decelerates below 15% or interest rates spike.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Ventas, Inc.'s 12-month outlook, with a consensus price target around $100.45 and implied upside of +8.0% versus the current price.
Average Target
$100.45
0 analysts
Implied Upside
+8.0%
vs. current price
Analyst Count
—
covering this stock
Price Range
$86 - $113
Analyst target range
The target price range spans from $86.00 (low) to $113.00 (high), representing a wide spread of 31.4% from low to high, indicating significant uncertainty about the stock's future performance. The high target of $113 implies a 21.4% upside, likely assuming continued strong senior housing performance and successful life science developments, while the low target of $86 suggests a 7.6% downside, possibly pricing in slower growth or higher interest rates. Recent institutional actions show a mix of ratings, with Barclays downgrading from Overweight to Equal Weight in July 2026, while others like Evercore ISI and Wells Fargo maintain positive stances, reflecting a generally constructive but cautious sentiment.
Drowning in data?
Find the real signal!
Bulls vs Bears: VTR Investment Factors
Ventas presents a compelling growth story with strong revenue acceleration, improving profitability, and a diversified portfolio, supported by a consensus Buy rating and a PEG ratio below 1. However, the stock trades at a significant premium to its earnings, carries a high debt load, and faces potential headwinds from elevated interest rates and recent analyst downgrades. The bull case is currently stronger, driven by operational momentum and favorable demographics, but the valuation leaves limited margin of safety. The key tension is whether the market's high earnings growth expectations (forward PE 101.7x) can be met, as any shortfall could trigger a sharp de-rating.
Bullish
- Strong Revenue Acceleration: Q1 2026 revenue grew 22.0% YoY to $1.657B, with sequential increases from $1.358B in Q1 2025 to $1.657B in Q1 2026, indicating robust operational momentum, particularly in senior housing.
- Analyst Consensus Buy with Upside: With 22 analysts, the consensus rating is 'Buy' (mean 1.61) and the average target price is $100.45, implying ~8% upside from the current $93.06. The high target of $113 suggests 21.4% potential upside.
- Improving Profitability Metrics: Operating margin improved to 14.2% in Q1 2026 from 11.6% in Q2 2024, and net margin rose to 3.4% from 1.6% in Q2 2024, reflecting better cost control and operating leverage.
- Low Beta and Diversified Portfolio: With a beta of 0.73, VTR offers lower volatility than the market. Its diversified healthcare portfolio across senior housing, medical offices, and life sciences reduces single-segment risk.
Bearish
- Elevated Valuation Multiples: Trailing PE is 140.7x and forward PE is 101.7x, significantly higher than the broader market and REIT averages, leaving little room for error in earnings expectations.
- High Debt Levels: Debt-to-equity ratio of 1.06 and current ratio of 0.96 indicate a leveraged balance sheet, which could strain cash flows if interest rates remain elevated.
- Negative Gross Margin in Q4 2025: Q4 2025 gross margin was -136.0% due to a large impairment charge, highlighting potential asset write-downs and volatility in reported earnings.
- Recent Price Volatility: The stock dropped 4.2% in the last month and experienced a -13.5% drawdown earlier in the period, indicating sensitivity to market sentiment and interest rate changes.
VTR Technical Analysis
Ventas is in a clear long-term uptrend, with the stock up 34.6% over the past year and currently trading at $93.06, which is 91.6% of its 52-week range (low of $66.38, high of $101.60). This positioning near the upper end of the range indicates strong momentum and investor confidence, though it also suggests the stock may be approaching overbought conditions. The 6-month price change of 8.3% and the YTD gain of 20.3% confirm a sustained upward trajectory, with the stock having recovered from a drawdown of -13.5% earlier in the period.
Beta
0.73
0.73x market volatility
Max Drawdown
-13.5%
Largest decline past year
52-Week Range
$66-$102
Price range past year
Annual Return
+34.6%
Cumulative gain past year
| Period | VTR Return | S&P 500 |
|---|---|---|
| 1m | -4.2% | +3.6% |
| 3m | +5.5% | +2.7% |
| 6m | +8.3% | +11.4% |
| 1y | +34.6% | +18.7% |
| ytd | +20.3% | +12.3% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
VTR Fundamental Analysis
Ventas has demonstrated robust revenue growth, with Q1 2026 revenue of $1.657 billion, up 22.0% year-over-year, and a clear acceleration from prior quarters (Q1 2025: $1.358 billion, Q2 2025: $1.421 billion, Q3 2025: $1.489 billion, Q4 2025: $1.566 billion). This growth is driven primarily by the Senior Living Operations segment, which generated $1.293 billion in revenue, representing 78% of total revenue, while the Outpatient Medical and Research Portfolio contributed $231 million and Triple Net Leased Properties added $123 million. The consistent sequential increases indicate strong operational momentum, particularly in senior housing, which is benefiting from favorable supply-demand dynamics and higher occupancy rates.
Quarterly Revenue
$1.7B
2026-03
Revenue YoY Growth
+22.0%
YoY Comparison
Gross Margin
39.6%
Latest Quarter
Free Cash Flow
$477428000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is VTR Overvalued?
Given that Ventas has positive net income, the PE ratio is the primary valuation metric. The trailing PE is 140.7x, while the forward PE is 101.7x, reflecting the market's expectation of significant earnings growth, as also indicated by a PEG ratio of 0.80. The wide gap between trailing and forward PE suggests that analysts anticipate a substantial increase in earnings, which is typical for a REIT in a recovery phase where depreciation and one-time items distort current earnings.
PE
140.7x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 45x~346x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
21.3x
Enterprise Value Multiple
Investment Risk Disclosure
Financial risks are notable: Ventas carries a debt-to-equity ratio of 1.06 and a current ratio below 1 (0.96), indicating potential liquidity pressure. Interest expenses totaled $156.1M in Q1 2026, consuming a significant portion of operating income. The negative gross margin in Q4 2025 (-136%) underscores the risk of asset impairments, which could recur and erode earnings. Additionally, the high payout ratio of 342% suggests dividends are not fully covered by earnings, though REITs often use FFO for coverage.
